Position in ALKS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,973,422
+$670,837 QoQ
Shares Held
84,090
+2.2% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Vident Advisory, LLC holds $33,979,992 across 23 Drug Manufacturers - Specialty & Generic names. ALKS ranks #5 (8.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
52,710 | $6,230,847 | |
| 2 | VTRS |
Viatris Inc
|
350,648 | $4,737,253 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
6,039 | $3,581,004 | |
| 4 | RDY |
Dr Reddys Laboratories Ltd
|
217,581 | $3,013,496 | |
| 5 | ALKS |
Alkermes plc.
This page
|
84,090 | $2,973,422 | |
| 6 | HLN |
Haleon plc
|
235,522 | $2,357,574 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
49,744 | $1,498,288 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
75,036 | $1,389,666 |
All Filings in ALKS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,973,422 | 84,090 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $2,302,585 | 82,294 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $2,442,900 | 81,430 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,704,469 | 59,576 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,876,097 | 56,817 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $1,901,927 | 66,131 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $1,928,062 | 68,884 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||